Dx & Vx Co., Ltd.

Equities

A180400

KR7180400004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
2,830 ^KRW	+4.43%		-0.70%	-52.12%

06-10	Malaysian Genomics Resource Forge Strategic Alliance with South Korean Healthcare Solutions Provider	MT
2023	Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	CI

KB12-1 Venture Fund managed by KB Investment Co., Ltd. acquired 4.17% stake in MG MED, Inc. from Psoma Therapeutics, Inc. for KRW 1.8 billion.

April 03, 2015 at 05:00 am

KB12-1 Venture Fund managed by KB Investment Co., Ltd. acquired 4.17% stake in MG MED, Inc. from Psoma Therapeutics, Inc. for KRW 1.8 billion on March 31, 2015. Psoma Therapeutics, Inc. sold 0.07 million shares at the price of KRW 25,000 per share. Post transaction, Psoma Therapeutics will not hold any shares of MG MED.

KB12-1 Venture Fund managed by KB Investment Co., Ltd. completed the acquisition of 4.17% stake in MG MED, Inc. from Psoma Therapeutics, Inc. on March 31, 2015.

Latest news about Dx & Vx Co., Ltd.

Malaysian Genomics Resource Forge Strategic Alliance with South Korean Healthcare Solutions Provider	06-10	MT
Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	12-20	CI
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers	27/06/23	CI
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors	13/06/23	CI
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.	23/05/23	CI
DxVx Appoints Kevin Kwon as New President	16/05/23	CI
DxVx Appoints Yong Gu Lee as CEO	16/05/23	CI
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	13/04/23	CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.	06/04/23	CI
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding	05/10/22	CI
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.	03/10/22	CI
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.	14/09/22	CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding	06/09/22	CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding	29/08/21	CI
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding	28/06/20	CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding	17/06/20	CI
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..	28/04/20	CI
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.	10/07/19	CI
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.	28/04/19	CI
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP	16/07/18	CI
GI Innovation, Inc. announced that it has received KRW 4.999995 billion in funding from Cancer Rop Co., Ltd.	12/07/18	CI
Cancer Rop Holdings Co., Ltd. singed a contract to acquire 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund for approximately KRW 9.5 billion.	10/07/18	CI
GI Innovation, Inc. announced that it expects to receive KRW 4.999995 billion in funding from Dx & Vx Co., Ltd.	27/06/18	CI
Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding	12/04/18	CI
Oxford Vacmedix UK Limited announced that it has received KRW 13.28575 billion in funding from Cancer Rop Co., Ltd.	05/03/18	CI

Chart Dx & Vx Co., Ltd.

Duration

Period

More charts

Company Profile

Dx & Vx Co Ltd, formerly Cancer Rop Co Ltd, is a Korea-based company primarily engaged in the molecular diagnosis business. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
DX & VX CO., LTD.	-52.12%	61.8M
EXACT SCIENCES CORPORATION	-43.39%	7.73B
GUARDANT HEALTH, INC.	+11.68%	3.7B
IOVANCE BIOTHERAPEUTICS, INC.	+0.37%	2.28B
BGI GENOMICS CO., LTD.	-21.21%	1.99B
VERACYTE, INC.	-23.77%	1.6B
CAREDX, INC	+18.25%	739M
SEEGENE, INC.	-10.04%	687M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-36.12%	461M
CURIOX BIOSYSTEMS CO., LTD	-4.47%	279M

Bio Diagnostics & Testing